株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界のペプチド治療薬市場:投与量・薬価・治験の考察 2024年

Global Peptide Therapeutics Market, Dosage, Price & Clinical Trials Insight 2024

発行 PNS Pharma 商品コード 506862
出版日 ページ情報 英文 1250 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.11円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

世界のペプチド治療薬市場:投与量・薬価・治験の考察 2024年 Global Peptide Therapeutics Market, Dosage, Price & Clinical Trials Insight 2024
出版日: 2018年05月30日 ページ情報: 英文 1250 Pages
概要

当レポートでは、世界のペプチド治療薬市場および治験動向について調査し、ペプチド治療薬の基礎、用途・適応症別によるペプチド治療薬、フェーズ・適応症・企業別によるペプチド治験の考察、治験中のペプチド薬剤に関する考察、上市済みペプチド治療薬の臨床・特許に関する考察、および将来のペプチド治療薬の展望などについて、まとめています。

第1章 ペプチド治療薬の登場:医薬品産業の新たな成長フロンティア

  • 候補薬としてのペプチド
  • ペプチド治療薬の必要性

第2章 小分子・タンパク質時代の幕開け

  • ペプチド vs. 小分子
  • ペプチド vs. タンパク質生物製剤

第3章 ペプチド治療薬の基礎

  • 新ペプチドの合理的設計
  • 規制承認の状況

第4章 ペプチド治療薬:コスト分析・市場考察 - 用途別

  • イメージングにおけるペプチドの用途
  • 疾患におけるペプチドの用途

第5章 代謝疾患におけるペプチドの用途

  • 代謝疾患の始まり
  • 代謝疾患向け認可済みペプチド治療薬
  • 代謝ペプチド市場

第6章 癌におけるペプチドの用途

  • 癌の始まり
  • ペプチド治療薬の投与量・薬価の分析
  • 癌向けペプチド治療薬:売上分析

第7章 心血管疾患におけるペプチドの用途

  • 心血管疾患の始まり
  • 心血管疾患向け認可済みペプチド治療薬
  • 心血管疾患向けペプチド治療薬:売上分析

第8章 HIV & 感染症におけるペプチドの用途

  • 感染症の始まり
  • 感染症向け認可済みペプチド治療薬
  • 感染症向けペプチド治療薬:売上分析

第9章 CNS疾患におけるペプチドの用途

  • CNS疾患の始まり
  • CNS疾患向けニューロペプチドドラッグデリバリー
  • 将来の市場可能性

第10章 世界のペプチド治療薬市場

  • 概要
  • ペプチド市場:用途別

第11章 世界のペプチド治験概要

  • 環状ペプチド
  • デプシペプチド
  • ジペプチド
  • グルカゴン様ペプチド
  • リポペプチド
  • ナトリウム利尿ペプチド
  • ニューロペプチド
  • オリゴペプチド
  • オピオイドペプチド
  • ペプチド
  • ペプチドホルモン
  • ペプチド断片
  • マルチペプチド

第12章 世界のペプチド市場:投与経路別

  • 投与経路における現在の動向
  • ペプチド製品の現在の動向

第13章 世界のペプチド市場:地域別

  • 北米
  • 欧州
  • アジア

第14章 世界のペプチド市場ダイナミクス

  • 好ましい指標
  • 課題

第15章 将来のペプチド治療薬市場の展望

  • 将来の動向
  • 将来の機会

第16章 環状ペプチド治験の考察:フェーズ・適応症・企業別

  • 研究から登録前
  • 上市済み

第17章 デプシペプチド治験の考察:フェーズ・適応症・企業別

第18章 ジペプチド治験の考察:フェーズ・適応症・企業別

第19章 グリコペプチド(糖ペプチド)治験の考察:フェーズ・適応症・企業別

第20章 リポペプチド治験の考察:フェーズ・適応症・企業別

第21章 ナトリウム利尿ペプチド治験の考察:フェーズ・適応症・企業別

第22章 ニューロペプチド治験の考察:フェーズ・適応症・企業別

第23章 オリゴペプチド治験の考察:フェーズ・適応症・企業別

第24章 オピオイドペプチド治験の考察:フェーズ・適応症・企業別

第25章 ペプチド治験の考察:フェーズ・適応症・企業別

第26章 マルチペプチド治験の考察:フェーズ・適応症・企業別

第27章 競合情勢

  • Amgen
  • Amylin Pharmaceuticals
  • Apitope Technology
  • BioPartners
  • BiondVax Pharmaceuticals Ltd
  • Boehringer Ingelheim
  • Circassia
  • Corden Pharma (Peptisyntha)
  • Eli Lily
  • Galena Biopharmaceuticals
  • GlaxoSmithKline
  • Hyperion Therapeutics
  • ImmunoCellular Therapeutics
  • Ipsen
  • Lonza
  • Merck
  • NovoNordisk
  • Par Pharmaceuticals
  • PeptiDream
  • Roche
  • Sanofi
  • Tarix Pharmaceuticals

図表

目次

Report Highlight:

  • Global Peptide Therapeutics Market Opportunity: More Than US$ 50 Billion
  • Cost Analysis & Market Insight into its Application
  • Dosage & Sales Analysis of Key Drugs
  • Global Peptide Drug Clinical Pipeline: 612 Drugs
  • Peptide Drug Application by Indication
  • Global Peptide Pipeline by Indication, Company & Phase
  • Marketed Peptide Drugs: 101 Drugs
  • Clinical Trials Insight by Peptide Classification

Peptide based therapeutics are currently experiencing a renaissance in the global market with collective sales of more than US$ 20 Billion in 2017. Therapeutics such as Lantus, from Sanofi has recently managed to become a blockbuster peptide therapeutic with record sales of over US$ 8 Billion in 2017. Overall, the global peptide therapeutics market is expected to surpass US$ 50 Billion by 2024 from less than US$ 30 Billion in 2018. The overall market growth will be driven by the increasing research and development expenditure by pharmaceutical organizations along with rapid entry of multiple peptide based drug in the market.

As of 2018, more than 100 approved peptide therapeutics for various clinical indications are commercially available in the global market. Additionally, a robust clinical pipeline currently has more than 100 type of therapeutics in late stage of clinical development with more than 200 types of therapeutics in pre-clinical stage.

Epidemic increase in clinical indications such as obesity, type II diabetes along with complex disease like cancer are key driving factors of the global peptide therapeutics market. Involvement of global pharmaceutical giants in mass production of peptide therapeutics and impressive investment in their research and development in segments like oncology, genetic disorders, rare disease and autoimmune disease is further bound to make it one of the most active and lucrative market in the future.

Owing to the high prevalence of lifestyle disorders like type II diabetes and obesity, the US currently leads the global peptide therapeutics market by a significant margin; followed by the European Union. However, with the alarming increase in patient base, the Asia-Pacific region is anticipated to emerge as one of the fastest growing peptide therapeutics market by 2024.

On the basis of application of peptide therapeutics, the global market has been segmented by indications such as peptide drugs for cancer therapeutics and metabolic disorders, for cardiovascular drug and devices to central nervous system ailments. Apart from these diseases peptide therapeutics have been applied for infections, respiratory disorders to hematological disorders. Of these, metabolic disorders, immunological and cancer are presently the class of disease that ranks in the massive share in the revenue of the global peptide therapeutics market. Over 300 companies are involved in developing more than 200 peptide based drugs in more than 300 oncology projects.

PNS Pharma report on the "Global Peptide Therapeutics Market" provides an in-depth analysis of the burgeoning peptide market. The report provides an accurate insight into the growth of the market over the last few years with special emphasis on growth trends, price analysis of products, therapy cost per patient, and sales analysis of peptide therapeutics, followed by vital factors that might impact the market during the forecast period. The report finally concludes with future projections regarding peptide therapeutics across various segments which clearly indicate it to be one of the leading markets of the future.

Table of Contents

1. Emergence of Peptide Therapeutics: New Growth Frontier For Pharmaceutical Industry

  • 1.1 Peptides as Drug Candidates
  • 1.2 Why Need for Peptide Therapeutics?

2. Cusp of Small Molecules & Proteins

  • 2.1 Peptides v/s Small Molecules
  • 2.2 Peptides v/s Protein Biologics

3. Fundamentals of Peptide Therapeutics

  • 3.1 Rational Design for Novel Peptides
  • 3.2 Aspects of Regulatory Approvals

4. Peptide Therapeutics - Cost Analysis & Market Insight into its Application

  • 4.1 Application of Peptides in Imaging
  • 4.2 Application of Peptides in Diseases

5. Peptide Therapeutics For Treatment of Metabolic Disorder

  • 5.1 Prologue to Metabolic Disorders
  • 5.2 Approved Peptide Drugs for Metabolic Disorders - Cost & Dosage Analysis
  • 5.3 Market of Metabolic Peptides

6. Peptide Therapeutics in Cancer - Drug Price & Therapy Cost Analysis

  • 6.1 Prologue to Cancer
  • 6.2 Dose & Price Analysis of Peptide Cancer Therapeutics
    • 6.2.1 Abralix
    • 6.2.2 Degarelix
    • 6.2.3 Octreotide
    • 6.2.4 Leuprolide
    • 6.2.5 Sipuleucel-T ( Provenge)
    • 6.2.6 Goserelin (Zoladex)
  • 6.3 Cancer Peptide Therapeutics - Sales Analysis

7. Peptide Therapeutics For Treatment of Cardiovascular Disease

  • 7.1 Prologue to Cardiovascular Diseases
  • 7.2 Approved Peptide Drugs in Cardiovascular Diseases
  • 7.3 Cardiac Peptide Therapeutics - Sales Analysis

8. Peptide Therapeutics For Treatment of HIV Infections

  • 8.1 Prologue to Infections
  • 8.2 Approved Peptide Therapeutics in Infections
  • 8.3 Anti-Infectious Peptides - Sales Analysis

9. Peptide Therapeutics For Treatment of CNS Disorders

  • 9.1 Prologue to CNS Disorders
  • 9.2 Neuropeptides Drug Delivery to CNS
  • 9.3 Future Market Potential

10. Global Peptide Therapeutics Market Current Scenario

  • 10.1 Overview
  • 10.2 Peptide Market by Application

11. Global Peptides Drug Clinical Pipeline Overview

  • 11.1 Cyclic Peptides
  • 11.2 Depsipeptides
  • 11.3 Dipeptides
  • 11.4 Glycopeptides
  • 11.5 Lipopeptides
  • 11.6 Natriuretic Peptides
  • 11.7 Neuropeptides
  • 11.8 Oligopeptides
  • 11.9 Opioid Peptides
  • 11.10 Peptides
  • 11.11 Multiple Peptides

12. Global Peptide Market by Route of Administration

  • 12.1 Current Trends in Route of Administration
  • 12.2 Current Trends over the Peptide Products

13. Global Peptide Market by Region

  • 13.1 North America
  • 13.2 Europe
  • 13.3 Asia

14. Global Peptide Drug Market Dynamics

  • 14.1 Favorable Parameters
  • 14.2 Challenges

15. Global Peptide Therapeutics Market Future Outlook

  • 15.1 Future Trends in Peptide Therapeutics
  • 15.2 Future Opportunities of Peptides Therapeutics

16. Cyclic Peptides Clinical Trials Insight by Phase, Indication & Company

  • 16.1 Preclinical till Preregistration
  • 16.2 Marketed

17. Depsipeptides Clinical Trials Insight by Phase, Indication & Company

  • 17.1 Preclinical till Preregistration
  • 17.2 Marketed

18. Dipeptides Clinical Trials Insight by Phase, Indication & Company

  • 18.1 Preclinical till Preregistration
  • 18.2 Marketed

19. Glycopeptides Clinical Trials Insight by Phase, Indication & Company

  • 19.1 Preclinical till Preregistration
  • 19.2 Marketed

20. Lipopeptides Clinical Trials Insight by Phase, Indication & Company

  • 20.1 Preclinical till Preregistration

21. Natriuretic Peptides Clinical Trials Insight by Phase, Indication & Company

  • 21.1 Preclinical till Preregistration
  • 21.2 Marketed

22. Neuropeptides Clinical Trials Insight by Phase, Indication & Company

  • 22.1 Preclinical till Preregistration
  • 22.2 Marketed

23. Oligopeptides Clinical Trials Insight by Phase, Indication & Company

  • 23.1 Preclinical till Preregistration
  • 23.2 Marketed

24. Opioid Peptides Clinical Trials Insight by Phase, Indication & Company

  • 24.1 Preclinical till Preregistration
  • 24.2 Marketed

25. Peptides Clinical Trials Insight by Phase, Indication & Company

  • 25.1 Preclinical till Preregistration
  • 25.2 Marketed

26. Multiple Peptides Clinical Trials Insight by Phase, Indication & Company

  • 26.1 Preclinical till Preregistration
  • 26.2 Marketed

27. Competitive Landscape

  • 27.1 Amgen
  • 27.2 Amylin Pharmaceuticals
  • 27.3 Apitope Technology
  • 27.4 BioPartners
  • 27.5 BiondVax Pharmaceuticals Ltd
  • 27.6 Boehringer Ingelheim
  • 27.7 Circassia
  • 27.8 Corden Pharma (Peptisyntha)
  • 27.9 Eli Lily
  • 27.10 Galena Biopharmaceuticals
  • 27.11 GlaxoSmithKline
  • 27.12 Hyperion Therapeutics
  • 27.13 ImmunoCellular Therapeutics
  • 27.14 Ipsen
  • 27.15 Lonza
  • 27.16 Merck
  • 27.17 NovoNordisk
  • 27.18 Par Pharmaceuticals
  • 27.19 PeptiDream
  • 27.20 Roche
  • 27.21 Sanofi
  • 27.22 Tarix Pharmaceuticals

List of Figures & Tables

  • Figure 2-1: Peptides as a Cusp of Small Molecule Drug & Proteins
  • Figure 2-2: Layout of Advantages of Peptide Drugs
  • Figure 3-1: Classification Based over the Sources of Peptide
  • Figure 3-2: Strategies for Screening of Novel peptides for Therapeutic Use
  • Figure 3-3: Methods for Generating Peptide Therapeutics at Large Scale
  • Figure 3-4: Whole General Concept of Manufacturing of Peptide Drugs
  • Figure 3-5: Process of Peptide Therapeutics FDA Approval Path
  • Figure 4-1: Global- Imaging Technology Market by Usage (%), 2018
  • Figure 4-2: Healthcare Imaging Market Share by Company (%), 2018
  • Figure 4-3: Diagrammatic Representation of the Peptidic Probe
  • Figure 4-4: Distribution of Therapeutic Drugs Approved by FDA by Chemical Species
  • Figure 4-5: Global - Peptide Therapeutics Market Size by Clinical Indications, 2018
  • Figure 5-1: Global - Prevalence of Metabolic Disorders by Region (%), 2018
  • Figure 5-2: Layout of Metabolic Syndrome Leading to Several Diseases
  • Figure 5-3: Global - Top 10 Countries with Diabetes Burden (Million), 2030
  • Figure 5-4: Global - Obesity in Women & Men by Region (Million), 2018
  • Figure 5-5: US- GLP-1 Agonist Drugs Comparative Cost Analysis (US$), 2018
  • Figure 5-6: Lantus - Monthly Cost Comparison by Country (US$), 2018
  • Figure 5-7: Global - Metabolic Peptide Market Size (%), 2018
  • Figure 6-1: Global - Cancer Cases per 100,000 People (Top 10), 2018
  • Figure 6-2: Abraxis - Dosage Analysis (Mg/Day)
  • Figure 6-3: Degarelix - Dose Analysis (Mg/Patient)
  • Figure 6-4: Degarelix - Price Analysis (US$/Injection Vial), 2018
  • Figure 6-5: Degarelix-Monthly & Annual Treatment Cost Analysis (US$/Patient), 2018
  • Figure 6-6: Octerotide - Recommended Dosage for Carcinoid Tumor (Mcg/Patient)
  • Figure 6-7: Octreotide - Recommended Dosage for VIPOmas (Mcg/Patient)
  • Figure 6-8: Octreotide - Injectable Solution Price Analysis (US$/Mcg Vial), 2018
  • Figure 6-9: Leuprolide -Adult Dosage Analysis for Prostate Cancer by Month (Mg)
  • Figure 6-10: Leuprolide -Adult Dosage Analysis for Endometriosis in Women (Mg)
  • Figure 6-11: Provenge - Price Analysis (US$), 2018
  • Figure 6-12: Global - Cancer Peptide Therapeutics Market Size (%), 2018
  • Figure 6-13: US - Velcade Market Sales (US$ Million), 2018
  • Figure 6-14: Global - Estimated Velcade Sales (US$ Billion), 2018 - 2024
  • Figure 6-15: Global - Kyprolis Saless (US$ Billion), 2013 - 2017
  • Figure 6-16: Global & US - Zoladex Sales (US$ Million), 2017
  • Figure 7-1: Global - Cardiovascular Mortality (%), 2018
  • Figure 7-2: Cardiovascular Peptide Therapeutics - Cost Analysis (US$//Patient), 2018
  • Figure 7-3: Global - Angiomax Sales (US$ Million), 2018
  • Figure 7-4: Global - Integrilin Sales (US$ Million), 2016 & 2017
  • Figure 8-1: Global - Top 10 Leading Causes of Death
  • Figure 8-2: Global - Distribution of AIDS Affected Patients by Region (%), 2018
  • Figure 8-3: Fuzeon - Global Sales (US$ Millions), 2015 - 2017
  • Figure 9-1: US - Prevalence of Alzheimer's disease (Million)
  • Figure 9-2: Alzheimer Disease Market Size (%), 2018
  • Figure 10-1: Global - Insulin Market Forecast (US$ Billion) 2018 - 2024
  • Figure 11-1: Global - Total Peptides Clinical Pipeline by Phase (%), 2018 till 2024
  • Figure 11-2: Global Total Peptides Clinical Pipeline by Phase (Number), 2018 till 2024
  • Figure 11-3: Global Cyclic Peptides Clinical Pipeline by Phase (%),2018 till 2024
  • Figure 11-4: Global Cyclic Peptides Clinical Pipeline by Phase (Number), 2018 till 2024
  • Figure 11-5: Global Depsipeptides Clinical Pipeline by Phase (%),2018 till 2024
  • Figure 11-6: Global Depsipeptides Clinical Pipeline by Phase (Number), 2018 till 2024
  • Figure 11-7: Global Dipeptides Clinical Pipeline by Phase (%),2018 till 2024
  • Figure 11-8: Global Dipeptides Clinical Pipeline by Phase (Number), 2018 till 2024
  • Figure 11-9: Global Glycopeptides Clinical Pipeline by Phase (%),2018 till 2024
  • Figure 11-10: Global Glycopeptides Clinical Pipeline by Phase (Number), 2018 till 2024
  • Figure 11-11: Global Lipopeptides Clinical Pipeline by Phase (%),2018 till 2024
  • Figure 11-12: Global Lipopeptides Clinical Pipeline by Phase (Number), 2018 till 2024
  • Figure 11-13: Global Natriuretic Peptides Clinical Pipeline by Phase (%),2018 till 2024
  • Figure 11-14: Global Natriuretic Peptides Clinical Pipeline by Phase (Number), 2018 till 2024
  • Figure 11-15: Global Neuropeptides Clinical Pipeline by Phase (%),2018 till 2024
  • Figure 11-16: Global Neuropeptides Clinical Pipeline by Phase (Number), 2018 till 2024
  • Figure 11-17: Global Oligopeptides Clinical Pipeline by Phase (%),2018 till 2024
  • Figure 11-18: Global Oligopeptides Clinical Pipeline by Phase (Number), 2018 till 2024
  • Figure 11-19: Global Opioid Peptides Clinical Pipeline by Phase (%),2018 till 2024
  • Figure 11-20: Global Opioid Peptides Clinical Pipeline by Phase (Number), 2018 till 2024
  • Figure 11-21: Global Peptides Clinical Pipeline by Phase (%),2018 till 2024
  • Figure 11-22: Global Peptides Clinical Pipeline by Phase (Number), 2018 till 2024
  • Figure 11-23: Global Multiple Peptides Clinical Pipeline by Phase (%),2018 till 2024
  • Figure 11-24: Global Multiple Peptides Clinical Pipeline by Phase (Number), 2018 till 2024
  • Figure 12-1: Therapeutic Peptide Based Drugs over Route of Administration
  • Figure 14-1: Illustration of Peptide Therapeutics Market Drivers
  • Figure 14-2: Major Challenges Faced by the Peptide Therapeutics
  • Figure 15-1: Global - Estimated Future Peptide Therapeutics Market Size by Clinical Indication (%), 2024
  • Figure 15-2: Global - Cancer Peptide Therapeutics Forecast (US$ Billion), 2018 - 2024
  • Figure 15-3: Global - Metabolic Disorders Peptide Therapeutic Market Forecast (US$ Billion), 2018 - 2024
  • Figure 15-4: Global - Cardiovascular Peptide Therapeutic Market Forecast (US$ Billion), 2018 - 2024
  • Figure 15-5: Global - CNS, HIV & Infection Peptide Therapeutics Forecast (US$ Billion), 2018 - 2024
  • Figure 15-6: Future Trends of Peptide Therapeutics
  • Figure 15-7: Global - Peptide Therapeutics Market Forecast (US$ Billion), 2018 - 2024

List of Tables

  • Table 2-1: Comparative Analysis of Small Molecules & Peptide Drugs
  • Table 2-2: Comparative Differentiation between Peptide & Protein Drugs
  • Table 5-1: Major Approved GLP-1 Peptide Drugs for Metabolic Disorders
  • Table 5-2: Layout of Insulin & its Analogs Cost in US
  • Table 6-1: Approved Commercialized Peptide Cancer Drugs
  • Table 7-1: Approved Peptide Drugs for Cardiovascular Diseases
  • Table 8-1: Approved Drugs for Infections
  • Table 9-1: Brief Characterization of Some Neuroprotective Peptides
  • Table 9-2: Potential Targets for Peptide Based Therapies in CNS Disorders
  • Table 12-1: List of Approved Peptide Drugs Since 2000